(SNDX) Syndax Pharmaceuticals, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(SNDX) Syndax Pharmaceuticals, Inc. Complete Analysis Pack
Visual. Strategic. Downloadable.
This Syndax Pharmaceuticals, Inc. BCG Matrix helps you see how the company’s products or business units may fit into the classic Stars, Cash Cows, Question Marks, and Dogs framework. The page already shows a real preview of the analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
Revuforj 2024 FDA approval
Revuforj, the brand for revumenib, got FDA approval in November 2024 as the first menin inhibitor for relapsed or refractory acute leukemia with KMT2A translocation in adults and children 1 year and older. That label opens a high-growth precision-oncology niche with few direct options and strong launch potential. By end-2025, it is Syndax Pharmaceuticals, Inc.’s clearest Star in the BCG matrix.
Revuforj KMT2A-r acute leukemia
KMT2A-rearranged acute leukemia is a rare, high-need niche, and Revuforj was built for that biology. KMT2A-r shows up in about 5% to 10% of acute leukemias, so every new test and referral can widen the addressable pool. With first-mover status and a targeted label, Syndax Pharmaceuticals, Inc. fits Star logic as adoption grows and treatment sequencing shifts.
Niktimvo 2024 cGVHD approval
Niktimvo, Syndax Pharmaceuticals, Inc.'s axatilimab-csfr, won FDA approval in 2024 for chronic graft-versus-host disease after 2 or more prior systemic therapies. cGVHD is still an active specialty market, with 2025 patient demand supported by ongoing transplant care and limited late-line options. As a new branded CSF-1R antibody, Niktimvo fits the Star quadrant: high-growth need and early launch momentum.
Niktimvo first-in-class CSF-1R therapy
Niktimvo is Syndax Pharmaceuticals, Inc.'s first-in-class CSF-1R antibody for cGVHD, targeting a biologically distinct immune-fibrotic pathway. In AGAVE-201, the pivotal trial, the overall response rate was 74.6%, supporting its differentiated profile. As a 2024 launch still in early uptake, it needs heavy access and promotion, but the growth runway fits Star status.
- First-in-class CSF-1R in cGVHD
- AGAVE-201 ORR: 74.6%
- Early launch, still scaling access
Two-commercial-product platform
By end-2025, Syndax Pharmaceuticals, Inc. had 2 approved oncology products, Revuforj and Niktimvo, both launched in late 2024 and still in scale-up mode. That puts the portfolio in Star territory: fast-growing, specialty-market assets that are still building share, not mature cash cows. Syndax is already seeing early commercial traction, with 2025 revenue still in launch phase rather than harvest mode.
- 2 approved products by end-2025
- Both in launch and expansion
- Star profile, not cash generator
Syndax’s 2024 Stars Are Scaling Fast, Not Mature Yet
Revuforj and Niktimvo are Syndax Pharmaceuticals, Inc.'s Stars: both launched in 2024, both target high-need specialty niches, and both were still scaling in 2025. Revuforj addresses KMT2A-rearranged acute leukemia, a 5% to 10% subset of acute leukemias, while Niktimvo posted a 74.6% ORR in AGAVE-201. That mix supports fast share gain, but not maturity yet.
| Asset | Star signal | Key data |
|---|---|---|
| Revuforj | First-mover | FDA 2024; KMT2A-r 5% to 10% |
| Niktimvo | Early growth | FDA 2024; ORR 74.6% |
What is included in the product
Detailed Word Document
Syndax’s BCG Matrix maps its drug portfolio to spot Stars, Cash Cows, Question Marks, and Dogs for smart capital allocation.
Editable Excel File
One-page BCG Matrix for Syndax Pharmaceuticals, Inc., to quickly spot growth, cash, and drag areas.
Reference Sources
Provides a credible source trail for Syndax Pharmaceuticals, Inc., helping decision-makers verify assumptions fast and trust the numbers.
Cash Cows
No mature franchise yet
Syndax Pharmaceuticals, Inc. does not yet have a classic cash cow at end-2025. Its 2 commercial brands, Revuforj and Niktimvo, are still in early launch, so revenue and cash generation are still ramping from a low base. With high growth and continued market-building, this is not the low-growth, high-share profile of a mature cash cow.
2024 launches still ramping
Revuforj and Niktimvo both launched in 2024, so Syndax Pharmaceuticals, Inc. is still funding sales force, medical, and payer access work for 2 new brands. That puts them in the ramp-up stage, not the stable, low-investment phase of a Cash Cow. With launches this recent, cash generation is still building, not milking.
R&D remains a cash user
Syndax is still funding R&D for 2 approved assets, plus follow-on studies and label expansion, so cash is still going out before it comes in. In FY2025, that spend keeps the company in invest-ahead mode, not a true cash-cow phase. In biotech, heavy R&D usually delays steady harvest and keeps margins under pressure.
Limited mature revenue base
Syndax Pharmaceuticals, Inc. does not yet have a large legacy portfolio of established medicines, so its revenue base is still thin. The mix is led by newly commercialized assets and development-stage programs, with no mature, slow-growth branded franchise to act as a cash cow.
That matters in the BCG Matrix: cash generation is still early, while spending stays tied to launch and R&D. Revenue in FY2025 remains concentrated in first-wave commercialization, not in a stable, high-margin older product base.
- Limited legacy medicines
- New launches drive revenue
- No mature cash cow yet
- R&D still absorbs cash
Collaboration cash, not product cash
Syndax Pharmaceuticals, Inc. still leans more on collaboration and licensing cash than on a mature product engine. In FY2025, that mix can support liquidity, but BCG cash cows are high-share, repeat sales businesses, not funding streams.
That matters because Syndax’s revenue base is still early and uneven, while R&D and launch costs stay heavy. Even with two approved assets, product cash has not yet turned into the steady, low-growth cash flow you expect from a true cash cow.
- Partnership cash helps liquidity.
- Licensing income is not product dominance.
- Cash cow = mature, high-share product.
- Syndax still lacks that profile.
Syndax Still Lacks a True Cash Cow as 2025 Sales Ramp Up
Syndax Pharmaceuticals, Inc. still has no true cash cow at FY2025 end. Revuforj and Niktimvo launched in 2024, so sales are still ramping and launch spend stays high. With 2 early commercial brands and ongoing R&D, cash generation is still building, not steady harvest.
| Cash Cow test | FY2025 view |
|---|---|
| Commercial brands | 2 |
| Launch year | 2024 |
| Profile | No mature cash cow |
Preview Before You Purchase
Syndax Pharmaceuticals, Inc. Reference Sources
You’re previewing the exact Syndax Pharmaceuticals, Inc. BCG Matrix file you’ll receive after purchase. The full document is the same version—professionally formatted, ready to download, and free of demo content or watermarks.
What you see here is the real report, not a sample. Once purchased, the complete Syndax Pharmaceuticals, Inc. BCG Matrix will be instantly available for your use, editing, or presentation.
Dogs
Entinostat legacy program
Entinostat is Syndax Pharmaceuticals, Inc.'s legacy HDAC inhibitor program and no longer drives the commercial story. With two approved oncology launches in 2025, Syndax's growth sits elsewhere, so entinostat has little strategic leverage. In BCG terms, an older asset with weak growth and minimal current revenue belongs in Dog territory.
Entinostat breast-cancer failure
Entinostat in breast cancer fits a Dog profile. The phase 3 E2112 study in hormone receptor-positive metastatic breast cancer did not turn into a durable commercial win, so the asset lost its best late-stage value case. It now ties up R&D focus without clear market-share upside, while Syndax Pharmaceuticals, Inc. has shifted capital to newer programs.
Entinostat unapproved in 2025
Entinostat stayed unapproved through 2025, so it had no FDA label and no branded market share. That makes its BCG profile clear: low growth, low share, and no commercial pull for Syndax Pharmaceuticals, Inc. In contrast, Syndax's 2025 growth came from approved assets, not Entinostat, which still generated no product revenue.
Low strategic fit asset
Syndax Pharmaceuticals, Inc. has shifted its strategic center toward menin inhibition and cGVHD, so Entinostat now sits outside the main growth thesis. When a program no longer supports the core commercial path, it is harder to justify fresh capital and management focus. That makes Entinostat a clear Dog candidate in the BCG Matrix.
- Outside Syndax Pharmaceuticals, Inc. core growth plan
- Weak fit with menin inhibition and cGVHD focus
- Lower case for new investment
Legacy pipeline drag
Entinostat is Syndax Pharmaceuticals, Inc.'s clearest legacy drag: an older asset that can still consume time, capital, and team focus without clear approval odds or market pull. In a portfolio built around Revuforj and Niktimvo, that makes it a classic Dog, since low-return programs tie up scarce resources instead of funding higher-value launches.
- Legacy assets can trap cash and attention.
- Entinostat is the main Dog example.
- Focus should stay on approved products.
Entinostat: Syndax’s Dead Weight Asset
Entinostat is Syndax Pharmaceuticals, Inc.'s Dog: an older, unapproved asset with no 2025 product revenue, no FDA label, and no clear share gain. Syndax's 2025 growth came from Revuforj and Niktimvo, so capital and management focus have moved on. With weak growth and low strategic fit, entinostat looks like a cash and attention drain.
| Asset | 2025 status | BCG fit |
|---|---|---|
| Entinostat | No approval, no revenue | Dog |
Question Marks
Revuforj frontline AML studies
Revuforj is already approved, but its frontline AML push is still in build-out, so it fits the Question Mark in Syndax Pharmaceuticals, Inc. BCG Matrix. New combinations in newly diagnosed AML target a large, high-growth pool, yet share stays low because these settings are not fully penetrated. If ongoing data stay positive, Revuforj could move from a small launch asset toward a larger Star.
Revuforj NPM1-mut AML expansion
NPM1-mut AML is a major menin-inhibition win for Revuforj, with the U.S. AML market supported by 20,000-plus new cases a year and broader molecular testing lifting identification of eligible patients. But Syndax’s share is still early after the 2024 U.S. launch, so revenue visibility remains thin. That mix of strong clinical need, growing testing, and uncertain share makes it a classic Question Mark.
Revuforj pediatric and broader leukemia use
Revuforj is still a Question Mark in pediatric and broader acute-leukemia use: its label covers patients 1 year and older, but real growth depends on physician adoption and more data. Syndax Pharmaceuticals, Inc. has not yet disclosed meaningful share in these newer segments, so the base is still small. If follow-on studies and real-world use expand, this could scale fast from a low starting point.
Niktimvo label expansion
Niktimvo, FDA-approved in 2024 for cGVHD, still has a very small share because it is a new brand. If Syndax proves benefit in earlier-line use and broader immune-fibrotic settings, the addressable market can widen fast, but those uses are still not fully defined. That mix of low current share and high expansion optionality puts Niktimvo in Question Mark territory.
Niktimvo sclerotic cGVHD follow-on work
Niktimvo’s sclerotic cGVHD follow-on work is a classic question mark: high growth, low share. The registrational AGAVE-201 study enrolled 241 patients, and the FDA approved Niktimvo in August 2024 for chronic GVHD after at least 2 prior lines, so the market is still early and evidence-led. If efficacy stays strong in the tougher sclerotic and refractory subset, uptake can expand fast.
- Sclerotic cGVHD is hard to treat.
- Evidence is still shaping adoption.
- Uptake can rise with strong efficacy.
- High-growth, low-share profile.
Revuforj and Niktimvo: High Upside, Early Adoption
Revuforj and Niktimvo are Question Marks for Syndax Pharmaceuticals, Inc.: both have approval, but share is still low and growth depends on adoption. Revuforj’s AML opportunity is large, with 20,000-plus U.S. AML cases a year, yet its 2024 launch is still early. Niktimvo, approved in August 2024 for cGVHD after 2 prior lines, also starts from a small base.
| Asset | Why Question Mark | Key data |
|---|---|---|
| Revuforj | Low share, high-growth AML | 20,000-plus U.S. AML cases/year |
| Niktimvo | New brand, early uptake | FDA approved Aug 2024 |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.